Agmatine is an endogenous neuromodulator that has been shown to have beneficial effects in the central nervous system, including antidepressant-like effects in animals. In this study, we investigated the ability of agmatine (0.1 mg/kg, p.o.) and the conventional antidepressant fluoxetine (10 mg/kg, p.o.) to reverse the behavioral effects and morphological alterations in the hippocampus of mice exposed to chronic corticosterone (20 mg/kg, p.o.) treatment for a period of 21 days as a model of stress and depressive-like behaviors. Chronic corticosterone treatment increased the immobility time in the tail suspension test (TST), but did not cause anhedonic-like and anxiety-related behaviors, as assessed with the splash test and the open field test (OFT), respectively. Of note, the depressive-like behaviors induced by corticosterone were accompanied by a decrease in hippocampal cell proliferation, although no changes in hippocampal neuronal differentiation were observed. Our findings provide evidence that, similarly to fluoxetine, agmatine was able to reverse the corticosterone-induced depressive-like behaviors in the TST as well as the deficits in hippocampal cell proliferation. Additionally, fluoxetine but not agmatine, increased hippocampal differentiation. Agmatine, similar to fluoxetine, was capable of increasing both dendritic arborization and length in the entire dentate hippocampus, an effect more evident in the ventral portion of the hippocampus, as assessed with the modified Sholl analysis. Altogether, our results suggest that the increase in hippocampal proliferation induced by agmatine may contribute, at least in part, to the antidepressant-like response of this compound in this mouse model of stress induced by chronic exposure to corticosterone.
Introduction
Depression is one of the most prevalent psychiatric disorders that affects up to 20% of the world population, and is often associated with high morbidity and mortality (Bromet et al., 2011; Nemeroff, 2007) . The main symptoms observed in depressive patients are decreased interest in pleasurable activities and ability to experience pleasure, weight gain or loss, disorders of sleep, recurrent thoughts of death or suicide, and anxiety (Berton and Nestler, 2006) . In particular, when depression is associated with anxiety, a significantly higher incidence of suicidal ideation, as well as social and occupational dysfunction, are reported (Adams et al., 2016) .
A growing body of evidence has suggested that both stress and depression are associated with hyperactivity of the hypothalamic-pituitary-adrenal axis (HPA) and overproduction of the glucocorticoid corticosterone in animal models of depression (Myers et al., 2014; Santana et al., 2015; Wang et al., 2015) . In addition, several studies have reported that chronic corticosterone exposure in rodents, a condition that mimics chronic stress, promotes depressivelike behaviors Pazini et al., 2016; Weng et al., 2016) . The hippocampus expresses a high density of glucocorticoid receptors (De Kloet et al., 1998; Pryce, 2008; Veldhuis et al., 1982) , thus being particularly vulnerable to the effects of stress and chronic corticosterone administration. Although the mechanisms underlying corticosterone-induced depressive-like behaviors are not fully understood, a decrease in hippocampal neurogenesis is postulated to play a key role in this effect (Miller and Hen, 2015; Saaltink and Vreugdenhil, 2014) .
Conversely, compounds that stimulate hippocampal neurogenesis, including antidepressant drugs, may counteract hippocampal neuronal loss and the depressive-like behaviors induced by stress or corticosterone administration (Malberg et al., 2000; Santarelli et al., 2003) . Accordingly, the administration of glucocorticoid receptor antagonists is also able to reverse the reduction in hippocampal neurogenesis induced by chronic administration of corticosterone (Mayer et al., 2006) . Additionally, corticosterone treatment has also been shown to alter the morphology of mature neurons, decreasing dendritic arborization and dendritic length (Yau et al., 2016) . In agreement, it has been show that the exposure of animals to unpredictable stress leads to dendritic atrophy and that this alteration is reestablished by treatment with antidepressants, a mechanism that seems to be essential for the effect of these drugs (Bessa et al., 2009 ).
One of the major limitations in the treatment of depression is that antidepressants only provide a complete remission of symptoms in about 50% of patients (Berton and Nestler, 2006) , being also associated with several side effects, which often reduce the adhesion of patients to treatment (Brunello et al., 2002; Cartwright et al., 2016; Demyttenaere, 1997; Serretti and Mandelli, 2010) . For these reasons, the development of alternative therapeutic strategies for depression is warranted. Within this scenario, our group has studied extensively the antidepressant-like effects of agmatine (Freitas et al., 2016b; Moretti et al., 2015; Neis et al., 2016a; Neis et al., 2016b; Zomkowski et al., 2002) an endogenous amine synthesized through decarboxylation of L-arginine by the enzyme arginine decarboxylase Regunathan et al., 1995; Reis and Regunathan, 2000) . Agmatine acts as a neuromodulator in the mammalian brain, since it can be transported into presynaptic terminals, stored in synaptic vesicles, released into the synapse through membrane depolarization, and up-taken by polyamine transporters (Goracke-Postle et al., 2007; Piletz et al., 2013; Reis and Regunathan, 1999) . We and others have shown that agmatine has antidepressant-like effects in the forced swim test (FST) and tail suspension test (TST), two predictive tests of antidepressant activity (Neis et al., 2014; Zomkowski et al., 2002; Zomkowski et al., 2005) , as well as in animal models of depression, including chronic unpredictable mild stress Taksande et al., 2013) , restraint stress (Freitas et al., 2014a; Sahin et al., 2016) , and following chronic administration of corticosterone in mice . On the other hand, agmatine was shown to possess pro-neurogenic properties in models of traumatic brain injury (Kuo et al., 2011) and chronic stress .
Given this background, this study aimed at examining the effects of agmatine treatment on anxiety and depressive-like behaviors as well as on adult hippocampal neurogenesis in a mouse model of chronic stress, induced by chronic corticosterone administration.
Materials and methods

Animals
Adult female Swiss mice (30-35 g), obtained from Central Animal Care Facility of the Federal University of Santa Catarina, were used in this study. Animals were maintained at 20-22°C with free access to water and food, under a 12/12 h light-dark cycle (lights on at 07:00 h). They were housed in groups of 15 animals per cage in 41 × 34 × 16 cm cages. All manipulations were carried out between 9:00 and 14:00 h and the cages were placed in the experimental room 24 h before testing for acclimatization. All animal procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Committee on Ethics of Animal Experimentation of the Federal University of Santa Catarina (Florianópolis, Brazil; Protocol Number: PP00795). All efforts were made to minimize animal suffering and to reduce the number of animals used in these experiments.
Drugs and treatment
The following drugs were used: agmatine, corticosterone (obtained from Sigma Chemical Co., St Louis, USA), and fluoxetine (obtained from Sigma Pharma, SP, Brazil). Drugs were dissolved in distilled water and appropriate vehicle-treated groups were assessed simultaneously. The drugs were administered orally (p.o.) by gavage (at 10 ml/kg body weight).
Experimental procedure
Animals were randomly divided into four experimental groups (8-10 mice/group) and treated for 21 days as follows: (1) vehicle, (2) vehicle + corticosterone (20 mg/kg), (3) corticosterone (20 mg/kg) + fluoxetine (10 mg/kg) and (4) corticosterone (20 mg/kg) + agmatine (0.1 mg/kg) (Fig. 1) . Fig. 1 . Timeline of experimental procedures. Adult male mice received a daily administration of vehicle, corticosterone (20 mg/kg, p.o.), corticosterone (20 mg/kg, p.o.) plus agmatine (0.1 mg/kg, p.o.), or corticosterone (20 mg/ kg, p.o.) plus fluoxetine (10 mg/kg, p.o.) for 21 days. 24 h after last administration (on day 22), all animals were submitted to the TST, the OFT and the splash test. After behavioral testing, mice were transcardially perfused and their brains were processed for immunohistochemistry analyses of hippocampal cell proliferation and neuronal differentiation.
Tail suspension test (TST)
Immobility time in the TST was assessed as described by (Steru et al., 1985) and previously reported by us (Freitas et al., 2014a; Neis et al., 2014) . Briefly, mice were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. For each mouse, immobility time was assessed during a 6 min period.
Open field test (OFT)
To assess the effects of agmatine on locomotor activity, mice were evaluated in the OFT as previously described (Kaster et al., 2005; Steru et al., 1985) . The apparatus consists of a wooden box measuring 40 × 60 × 50 cm. The floor of the arena was divided into twelve equal squares: four in the center and eight in the periphery. The number of squares crossed with all paws (i.e., number of crossings), the number of entries (crossing the squares with four paws) and the time spent in the center were measured during a 6 min period (Prut and Belzung, 2003) . The apparatus was cleaned with a solution of 10% ethanol between trials to eliminate animal clues.
Splash test
Ten minutes after the OFT, animals were submitted to the splash test. Animals were individually placed in clear Plexiglas boxes (9 × 7 × 11 cm) and a 10% sucrose solution was squirted onto the dorsal coat of each mouse . Because of its viscosity and palatable flavor, normal animals engage in grooming behavior once their fur is dirtied by this solution. Thus, the latency to initiate grooming and the total time engaged in this behavior were manually recorded for a period of 5 min as an index of self-care motivational behavior and an indication of anhedonia (Willner, 2005) . To hide any animal clues, the apparatus was cleaned with a solution of 10% ethanol between tests.
Tissue processing
Animals were deeply anesthetized with an intraperitioneal (i.p.) injection of chloral hydrate (40%, i.p.) and transcardially perfused with 0.9% sodium chloride (NaCl) followed by 4% paraformaldehyde (PFA). The brains were removed and left in 4% PFA overnight at 4°C and then transferred to 30% sucrose. Following saturation in sucrose, serial coronal sections were obtained on a vibratome (Vibratome, Series 1000, St. Louis, MO, USA®) at 30 μm thickness. Sections were collected into a 1/6 section-sampling fraction and stored in 0.1 M phosphatebuffered saline (PBS) with 0.5% sodium azide at 4°C.
Immunohistochemistry
To evaluate hippocampal cell proliferation, immunohistochemistry against the endogenous cell cycle proteins Ki-67 and proliferating cell nuclear antigen (PCNA) was performed. Ki-67 is a mitotic marker that is expressed during all active phases of the cell cycle (G1, S, G2 and M) (Scholzen and Gerdes, 2000) , whereas PCNA is expressed during all active phases of the cell cycle and for a short period of time once cells become post-mitotic (Christie and Cameron, 2006; Ino and Chiba, 2000) . Two adjacent series of brain sections were incubated twice in 10 mM citric acid (dissolved in 0.1 M PBS, pH = 6.0) for 5 min at 95°C to completely expose the antigens. After rinsing in 0.1 M PBS, sections were quenched in 3% H 2 O 2 and 10% methanol in 0.1 M PBS for 10 min at room temperature (RT). Following thorough rinsing in 0.1 M PBS, tissue was blocked with 5% blocking solution (5% normal goat serum in 0.1 M PBS with 0.25% Triton X-100) and incubated with either a rabbit polyclonal primary antibody against Ki-67 (1:500; Vector Laboratories, Burlingame, CA, USA) or a rabbit polyclonal antibody against PCNA (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 48 h at 4°C. The sections were then incubated with a biotin-conjugated goat anti-rabbit IgG secondary antibody (1:200; Vector Laboratories) in 5% blocking solution at RT for 2 h.
To evaluate neuronal commitment and maturation, immunohistochemistry against doublecortin (DCX) and NeuroD was performed. DCX is a microtubule-associated protein specifically expressed in migrating neuroblasts (i.e., immature neurons (Brown et al., 2003; Couillard-Despres et al., 2001; Couillard-Despres et al., 2005; Gleeson et al., 1998) , whereas NeuroD is an helix-loop-helix transcription factor that is expressed during the early stages of neuronal differentiation (Gao et al., 2009; Miyata et al., 1999) . Two adjacent series of brain sections were quenched in 3% H 2 O 2 and 10% methanol in 0.1 M PBS for 15 min at RT. Following thorough rinsing in 0.1 M PBS, tissue was blocked with 5% blocking solution (5% normal horse serum in 0.1 M PBS with and 0.25% Triton X-100) and incubated with either a goat polyclonal primary antibody against DCX (1:400; Santa Cruz Biotechnology) or a goat polyclonal primary antibody against NeuroD (1:200; Santa Cruz Biotechnology) for 48 h at 4°C. Then, sections were incubated with a biotin-conjugated horse anti-goat IgG secondary antibody (1:200; Vector Laboratories) in 5% blocking solution at RT for 2 h.
For all immunohistochemistry procedures, the bound antibodies were visualized using an avidin-biotinperoxidase complex system (Vectastain ABC Elite Kit, Vector Laboratories) with 3,3′-diaminobenzidine (DAB; Vector Laboratories) as a chromogen. The sections were mounted onto 2% gelatin-coated microscope slides, dehydrated in a series of ethanol solutions of increasing concentrations followed by 5-minute incubation with xylene P.A., and coverslipped with Entellan new (Merk, USA).
Morphological quantification
All morphological analyses were performed on coded slides, with the experimenter blinded to the identity of the samples, using an inverted microscope (Olympus IX83, Center Valley, PA, USA) equipped with 20 × and 40 × objectives. A 17-megapixel color digital camera (Olympus DP73, Olympus) and the CellSens Dimension 1.12 (Olympus) software were used for image capture. The total number of Ki-67-, PCNA-, NeuroD-, and DCX-immunopositive cells present in the SGZ of the entire DG (from 1.34 to 3.16 posterior to Bregma; approximately ten coronal sections per brain), the dorsal DG (from 1.34 to 2.18 posterior to Bregma; approximately five coronal sections per brain) and the ventral DG (from 2.30 to 3.16 posterior to Bregma; approximately five coronal sections per brain) (Franklin, 2008) were quantified by manually counting all DAB-positive cells present within 2-3 cell diameters of the SGZ. Results were expressed as the total number of labeled cells in the DG sub-region of the hippocampus by multiplying the average number of labeled cells per DG section by the total number of 30-μm-thick sections containing either the entire DG SGZ (60 slices), the dorsal DG SGZ (30 slices), or the ventral DG SGZ (30 slices). Images were processed with Microsoft PowerPoint 2010. Only contrast enhancements and color level adjustments were made.
Sholl analysis
Linear Sholl analysis (Sholl, 1953) protocol was adapted from . In brief, one section containing the dorsal hippocampus was randomly selected from each animal from each of the experimental groups (n = 5, except Corticosterone treated group, n = 4). Sections were observed in a light microscope (Olympus BH-2) at 1000× magnification and five non-overlapping fields were randomly selected from each dorsal hippocampus. One DCX-positive cell with tertiary dendritic branches was traced for each field using camera Lucida also at 1000× magnification. If there were no DCX-positive cell with tertiary branches present in a given field, a cell with secondary branches was traced instead. Accordingly, in the absence of cells with secondary branches, a cell with a primary branch was selected and traced. This process resulted in five traces of DCX-positive cells from the dorsal hippocampus of each experimental animal. Drawings were then digitalized using a table scanner at 300 Dpi and number coded in a way that the experimenter was blind to the experimental conditions. Dendritic complexity analysis was performed using a custom imaging-processing algorithm written in MATLAB (MathWorks®, Natick, MA.) capable of calculating the number of dendritic intersections and dendritic tree length. The process described above was repeated for the ventral hippocampus in a different, randomly selected section, yielding a total of 10 DCX-positive cell traces from each animal (5 from dorsal and 5 from ventral hippocampus). Consequently, this process resulted in a total 50 cell traces per experimental group (except for the corticosterone treated group, n = 40).
Statistical analysis
All data are presented as mean ± S.E.M. Differences among experimental groups were determined by one-way analysis of variance (ANOVA) followed by Newman-Keuls post-hoc tests when appropriate. A p value of p < 0.05 was considered to be statistically significant. Dendritic intersection data was analyzed by Two-way repeated measure ANOVA followed by Bonferroni post-hoc. Dendritic tree length data was analyzed by One-way ANOVA followed by Tukey post-hoc. All statistical analysis were performed with the aid of STATISCA 8 software (StatSoft, Tulsa, OK).
Results
Effects of agmatine or fluoxetine treatment in the depressive-like behaviors induced by chronic administration of corticosterone
Animals were treated for a period of 21 days with corticosterone (20 mg/kg, p.o.) with or without fluoxetine (10 mg/kg, p.o.) or agmatine (0.1 mg/kg, p.o.) and were then evaluated in the TST, to assess immobility time as a proxy of depressive-like behavior. A one-way ANOVA revealed a significant effect of treatment [F (3, 31) = 6.44, p = 0.002]. Further post-hoc analyses revealed that corticosterone induced a significant increase in immobility time in the TST (p < 0.01) and this effect was prevented by both fluoxetine (10 mg/kg, p.o.) (p < 0.01) and agmatine (0.1 mg/kg, p.o.) (p < 0.05) treatment ( Fig. 2A) . To discard any potential effects of the various treatments on locomotor activity, the OFT was also performed. Treatment with corticosterone, fluoxetine, and agmatine had no significant effect on locomotor activity [F (3, 36) = 2.36, p = 0.087] (Fig. 2B) .
Effects of agmatine or fluoxetine treatment in anhedonic behaviors induced by chronic administration of corticosterone
To evaluate the potential effects of corticosterone, fluoxetine, and agmatine on self-care motivational-related behaviors and the occurrence of anhedonic-related behaviors, the splash test was used. The total time spent grooming and the latency to initiate grooming were recorded ( Fig. 2 C and D) . However, a one-way ANOVA revealed no significant effects of treatment in the latency to initiate grooming [F (3, 36) = 1.51, p = 0.227] and in the total time engaged in this behavior [F (3, 35) = 2.48, p = 0.077]. These results indicate that, in this study, the occurrence of self-care motivational-related behaviors and/or anhedonia were not altered by corticosterone treatment.
Effects of agmatine or fluoxetine treatment in anxiety-related behaviors induced by chronic administration of corticosterone
To evaluate the potential effects of corticosterone, fluoxetine, and agmatine on the occurrence of anxiety-related behaviors, the OFT was used and the number of entries in the center of the open field arena was estimated as a proxy of anxiety-related behavior (Fig. 2E) . A one-way ANOVA revealed a significant effect of treatment [F (3, 36) = 3.43, p = 0.027] with regards to the number of entries in the center of the arena, with animals treated with both corticosterone and agmatine showing a significant increase in the number of entries when compared with the vehicle-treated group (p < 0.05). In addition, the total time spent in the center of the arena was also measured [F (3, 36) = 2.15, p = 0.110] however only a non-significant trend towards an increase in the time spent in the center was found in animals treated with both corticosterone and agmatine (Fig. 2F) . Overall, these results suggest that in addition to its antidepressant-like properties, agmatine may also act as an anxiolytic.
Effects of corticosterone, agmatine and fluoxetine on hippocampal cell proliferation
To assess the effects of treatment with either agmatine or fluoxetine on hippocampal cell proliferation following chronic corticosterone administration, immunohistochemistry against Ki-67, and endogenous cell cycle marker that is expressed during all active phases of the cell cycle (Scholzen and Gerdes, 2000) , was performed. A one-way ANOVA revealed a significant effect of treatment on the total number of Ki-67-positive cells present along the entire SGZ of the hippocampal DG [F (3, 27) = 5.74, p = 0.003]. Further post-hoc analysis revealed a significant decrease in the number of proliferating cells in corticosteronetreated mice when compared with their vehicle-treated controls (p < 0.05), an effect that was reversed by both agmatine (p < 0.05) and fluoxetine treatment (p < 0.05) (Fig. 3 A and C) . In addition, cell proliferation in the dorsal and ventral aspects of the hippocampal DG were also individually analyzed. Similarly to what was observed in the entire DG, a significant effect of treatment was detected both in the ventral [F (3, 26) = 3.75, p = 0.022, Fig. 3E ] and the dorsal [F (3, 26) = 6.76, p = 0.001; Fig. 3G ] DG. Further post-hoc analyses revealed that chronic corticosterone treatment resulted in a reduction in the number of Ki-67-positive cells both in the ventral (p < 0.05) and dorsal (p < 0.01) aspects of the hippocampal DG. Furthermore, both agmatine and fluoxetine treatment were able to revert this reduction in both DG aspects (ventral DG: p < 0.05; dorsal DG: p < 0.01).
Hippocampal cell proliferation was further assessed by immunohistochemistry against PCNA, another endogenous cell cycle marker that is expressed during all active phases of the cell cycle and for a short period once cells become post-mitotic (Christie and Cameron, 2006; Ino and Chiba, 2000) . A one-way ANOVA revealed a significant effect of treatment on the total number of PCNA-positive cells present along the entire SGZ of the hippocampal DG [F (3, 15) = 4.59, p = 0.017]. However, further post-hoc analysis failed to reveal a significant difference in the number of PCNA-positive cells between corticosterone-treated mice and their vehicle-treated controls. Nevertheless, co-administration of either agmatine (p < 0.05) or fluoxetine (p < 0.05) significantly increased the number of PCNA-positive cells along the entire DG axis (Fig. 3B and D) . Interestingly, this effect appears to be localized to the ventral DG [F (3, 16) = 4.37, p = 0.019; Fig. 3F ], where a significant increase in the number of PCNA-positive cells induced by agmatine was also detected (p < 0.05). On the other hand, in the dorsal DG statistical analysis failed to reveal a significant effect of treatment [F (3, 16) = 2.11, p = 0.138; Fig. 3H ].
Effects of corticosterone, agmatine and fluoxetine on hippocampal neuronal differentiation
To assess the effects of treatment with either agmatine or fluoxetine on hippocampal neuronal commitment following chronic corticosterone administration, immunohistochemistry against NeuroD, an helix-loop-helix transcription factor that is specifically expressed during in newly differentiated neurons within the hippocampal DG (Miyata et al., 1999) was performed. A one-way ANOVA revealed a significant effect of treatment on the total number of NeuroD-positive cells present along the entire SGZ of the hippocampal DG [F (3, 32) = 3.78, p = 0.019; Fig. 4A and C]. However, further post-hoc analysis only revealed a significant increase in the number of NeuroD-positive immature neurons in the DG of animals treated with both corticosterone and fluoxetine-when compared with their vehicle-treated counterparts (p < 0.05). On the other hand, animals treated with either corticosterone alone or corticosterone plus agmatine showed similar levels of DG neuronal commitment when compared with vehicle-treated mice. Similar results were also obtained both in the ventral [F (3, 31) = 4.20, p = 0.013; Fig. 4E ] and dorsal [F (3, 32) = 7.46, p < 0.01; Fig. 4G ] aspects of the hippocampal DG, with fluoxetine treatment resulting in a significant increase in the number of NeuroD-positive cells both in the ventral (p < 0.05 as compared with corticosterone plus agmatinetreated mice; p < 0.01 as compared with vehicle-treated mice) and dorsal aspects (p < 0.01 as compared to all other treatment groups) of the DG.
In addition, to evaluate the effects of either agmatine or fluoxetine treatment on hippocampal neuronal differentiation following chronic corticosterone administration, immunohistochemistry against DCX, a cytoskeletal protein expressed in immature neurons (i.e., neuroblasts) (Brown et al., 2003 Fig. 4H ] aspects of the hippocampal DG, with post-hoc analyses demonstrating that both fluoxetine (p < 0.01) and agmatine (p < 0.05) treatment result in significant increases in the number of DCX-positive neuroblasts both in the ventral and dorsal DG aspects.
Effects of corticosterone, agmatine and fluoxetine on dendritic complexity
To evaluate the effects of agmatine or fluoxetine treatment on the length and dendritic arborization of immature neurons in the hippocampal DG after chronic corticosterone administration, immunohistochemistry was performed for the DCX protein, and a modified Sholl analysis was then performed (Ristanovic et al., 2006; Wang Fig. 5D and B]. Further posthoc analysis revealed that a significant increase in the number of intersections only occurred in animals treated with either fluoxetine or agmatine (p < 0.05). Similarly, both in the ventral DG [F (69, 2184) = 3.24, p < 0.05; Fig. 5E ] and the dorsal DG [F (69, 2184) = 1.56, p < 0.05; Fig. 5F ], a significant increase in the number of intersections was observed in animals treated with both corticosterone and fluoxetine (p < 0.05) or corticosterone and agmatine (p < 0.05).
With regards to dendritic length, a one-way ANOVA demonstrated a significant effect of treatment on dendrite length [F (3, 186) = 7.23, p < 0.01; Fig. 5C and A]. Post-hoc analysis revealed a significant increase of dendritic length in mice treated with corticosterone and agmatine (p < 0.05) or corticosterone and fluoxetine (p < 0.05) when compared with the vehicle-treated group. Of note, this effect was exclusively due to an increase in dendritic length in the ventral DG [F (3, 91) = 8.86, p < 0.01; Fig. 5C ], as no significant changes in this parameter were noted in the dorsal DG [F (3, 91) = 1.01, p = 0.388; Fig. 5C ].
Discussion
Several lines of evidence have indicated that repeated corticosterone administration in rodents mimics the neurochemical and behavioral alterations elicited by stress, and resembling those observed in depressive patients. Particularly, chronic administration of corticosterone has been shown to increase the immobility time of mice in the TST and the forced swim test (FST), and to cause anhedonic behavior, as demonstrated by decreased sucrose consumption, both of which are considered behavioral alterations that replicate depressive symptoms (Demuyser et al., 2016; Pazini et al., 2015; Yan et al., 2016; Zhao et al., 2009) . Indeed, major depression is closely related to exposure to chronic stress, since individuals exposed to stressful life situations have a strong risk of developing depressive episodes, which are often associated with anxious symptoms. In addition, in animal models of depression, chronic exposure to different stressors also induces depressive-like behaviors (de Kloet et al., 2005; de Kloet et al., 2016; Kendler et al., 2003; Kumar and Mondal, 2016; Mazure et al., 2000) .
In the present study, chronic treatment with corticosterone induced a depressive-like behavior in the TST, an effect counteracted by treatment with the conventional antidepressant fluoxetine as well as agmatine. The detrimental effect of corticosterone in the TST showed here is in agreement with previous studies using either the same protocol employed in this study (Pazini et al., 2015) , or different corticosterone doses and routes of administration, as well as different animal strains (Fenton et al., 2015; Gong et al., 2016; Weng et al., 2016) . In addition, the present results also confirm the ability of fluoxetine to reverse the depressive-like effect induced by chronic administration of corticosterone (Ali et al., 2015; Pazini et al., 2016; Weng et al., 2016) . With regards to agmatine, its antidepressant effects have been previously shown in the same model of depression , as well as in different animal models of this mood disorder, including those induced by exposure to acute restraint stress (Freitas et al., 2014b) , chronic unpredictable stress , and administration of either tumor necrosis factor (TNF-α) (Neis et al., 2014) or lipopolysaccharide (Gawali et al., 2016) .
While in our previous studies this same model of chronic corticosterone administration was characterized by both increased immobility time in the TST and FST as well as anhedonic behavior (as assessed with the sucrose consumption test) (Pazini et al., 2016) , in the present study we were unable to replicate the occurrence of anhedonic behavior, as evidenced by the lack of effect of chronic corticosterone administration on the splash test (which also provides a measure of anhedonia) . While the reasons for this are presently unclear, they may be related with inbreeding of our mouse colony and the consequent development of a partial resistance to stress and/or corticosterone. Indeed, in a recent study from our group using the same mouse colony, we were also unable to observe anhedonic behavior following chronic unpredictable stress . Indeed, just as strains may show phenotypic behavioral variation influencing their performance in different behavioral tests, it is worth noting that inbred strains may also show variability in individual responses and behaviors (Jacobson and Cryan, 2007) . In addition, maternal stress and intrauterine factors can affect the behavioral characteristics of offspring (Lathe, 2004) . On the other hand, in adults, factors such as repeated handling and procedural stress (Balcombe et al., 2004; Bettio et al., 2016b; Jacobson and Cryan, 2007) , dominance status and endocrine oscillations during the estrous cycle in females, are all recognized sources of behavioral diversity within the same animal colony (Lathe, 2004) . Thus, understanding how these factors amplify and/or modify the behavioral spectrum displayed by otherwise identical animals may improve the reliability of behavioral findings among studies.
On the other hand, it might also be possible that the mouse strain used in this study (Swiss mice) may be less reliable with regards to demonstrating behavioral deficits following exposure to either stress and/or corticosterone, when compared with other mouse strains. Indeed, a study comparing two mouse strains submitted to a protocol of mild chronic unpredictable stress demonstrated decreased grooming behaviors in BALB/C mice but not in Swiss mice, suggesting that indeed Swiss mice might be less sensitive to stress when compared with other Dendritic length in the entire DG, the ventral DG and the dorsal DG (C). Dendritic arborization in the entire DG (D), the ventral aspect of the DG (E), and the dorsal aspect of the DG (F), estimated as the number of intersections with respect to the distance from the soma (i.e., dendritic length). Data are presented as mean ± S.E.M. (N = 5-4 animals). Results were analyzed by one-way ANOVA followed by the Tukey post hoc test or repeated measures ANOVA followed by the Bonferroni post hoc test. *p < 0.05, animals treated with both corticosterone and fluoxetine as compared with the vehicle-treated group; # p < 0.05, animals treated with both corticosterone and fluoxetine as compared with the corticosteronetreated group; $ p < 0.05, animals treated with both corticosterone and agmatine as compared with the vehicle-treated group; @ p < 0.05, animals treated with both corticosterone and agmatine as compared with the corticosterone-treated group. Cortico = corticosterone, Agm = agmatine, Flx = Fluoxetine.
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Progress in Neuropsychopharmacology & Biological Psychiatry 81 (2018) 395-407 commonly used mouse strains (Yalcin et al., 2008) . Thus, we postulate that either repeated inbreeding of our Swiss mouse colony, natural variability within our inbred colony, and/or the decreased reliability of this particular mouse strain in showing overt behavioral deficits following exposure to stress and/or corticosterone may underlie the attenuation of the behavioral (and neurogenic; see below) deficits reported in the present study. Taking into account the extensive comorbidity between depression and anxiety, the present study also evaluated the effects of agmatine in anxiety-related behaviors, namely the number of entries and the time spent in the center of the open field. However, chronic administration of corticosterone, while promoting a depressive-like behavior, did not induce an anxious-like behavior in mice. These findings are consistent with other studies, in which chronic administration of corticosterone did not result in an increase in anxiety-related behaviors in rodents (Demuyser et al., 2016; Gregus et al., 2005) . Nevertheless, agmatine treatment had an anxiolytic effect, significantly increasing the number of entries in the center of the open field. This observation is in line with the reported anxiolytic properties of agmatine, which can be seen following either single or repeated administration, both in rats and mice (Gong et al., 2006) .
Several studies have demonstrated that excessive release of glucocorticoids is capable of causing dendritic atrophy as well as decreased cell proliferation and neuronal differentiation in the hippocampus, mechanisms that appear to be correlated with the development of a depressive-like behavior (Duman, 2014; Lanfumey et al., 2008; Zhao et al., 2008) . In agreement, the present study shows that chronic administration of corticosterone significantly decreased cellular proliferation in the hippocampal DG, as assessed by immunohistochemistry against two different endogenous cell cycle markers, Ki-67 and PCNA. Conversely, both agmatine and fluoxetine, were able to prevent this decrease in hippocampal cell proliferation induced by corticosterone, an effect that may underlie, at least in part, the antidepressant properties of these two compounds. Indeed, the ability to enhance hippocampal neurogenesis in general and cell proliferation in particular seems to play a crucial role in the mechanism of action of antidepressant drugs (Bessa et al., 2009; Santarelli et al., 2003) .
It is well established that the dorsal and ventral aspects of the hippocampus constitute two functionally distinct structures (Fanselow and Dong, 2010) . Indeed, while the dorsal hippocampus (i.e., the posterior hippocampus in primates) is specifically involved in spatial learning and memory, the ventral hippocampus (i.e., the anterior hippocampus in primates) appears to be mainly implicated in the regulation of stress responses, emotions, and affect (Bannerman et al., 2004; Degroot and Treit, 2004) . Accordingly, the antidepressant responses of several conventional antidepressants and putative antidepressant agents have been reported to be associated with increased neurogenesis in the ventral DG Pazini et al., 2016; Zhou et al., 2016) . In the present study, fluoxetine and agmatine significantly increased the number of Ki-67-positive cells both in the ventral and dorsal aspects of the hippocampal DG of corticosterone-treated mice. This is in contrast with previous studies, where the proliferative capacity of fluoxetine was only noted in the ventral DG (Pazini et al., 2016; Zhou et al., 2016) . While the reasons for these discrepancies are not fully understood, differences among animal cohorts used in the various studies, as well as the protocols of drug administration and/or assessment of hippocampal cell proliferation may account, at least in part, for these results. Nevertheless, when cell proliferation was assessed with PCNA, an alternate endogenous cell cycle marker, a significant increase in cell proliferation was only detected in the ventral DG of corticosterone-exposed mice that were treated with agmatine, suggesting that agmatine may preferentially affect cell proliferation in the ventral aspect of the hippocampal DG.
In addition to cell proliferation, the present study also assessed neuronal commitment (through immunohistochemistry against NeuroD) and neuronal differentiation (through immunohistochemistry against DCX). Contrary to what we have previously reported (Pazini et al., 2016) , in this study chronic exposure to corticosterone did not significantly affect the number of both NeuroD-and DCX-positive immature neurons in the hippocampal DG. While the reasons for this are presently unclear, as discussed above, they may be related with the natural variability commonly noted in inbred colonies and/or the development of a partial resistance to stress and/or corticosterone in our inbred colony, as evidenced by our recent inability to replicate anhedonic behaviors following either chronic unpredictable stress or corticosterone treatment (present study).
In any case, other studies have also failed to detect an effect of corticosterone on hippocampal neuronal differentiation both in vitro (Yu et al., 2004) and in vivo (Rainer et al., 2012) . For example, treatment of cultured hippocampal progenitor cells with different concentrations of corticosterone had no effect on the levels of NeuroD mRNA, as assessed by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) (Yu et al., 2004) . In addition, male C57BL/6 mice subjected to chronic corticosterone treatment showed reduced hippocampal cell proliferation (as assessed by a decrease in the number of BrDU-positive cells) in both the dorsal and ventral aspects of the hippocampus, but no changes in neuronal maturation, as assessed with DCX (Rainer et al., 2012) . Similarly, no changes in hippocampal cell survival were seen in a predator stress model, despite an increase in corticosterone levels in animals submitted to this type of stress (Lau et al., 2016) . Overall, the effects of stress in general and corticosterone in particular on adult hippocampal neuronal differentiation appeared to be mixed and dependent on the mouse strain, colony (and factors affecting the colony at any given time), as well as dose, timing, and route of corticosterone administration, with some studies showing no effects of corticosterone on hippocampal neuronal differentiation (Kott et al., 2016; Rainer et al., 2012; Yu et al., 2004 ) present study) and others showing a decrease in the number of hippocampal differentiating neurons following cortiscosterone treatment (Kott et al., 2016; Pazini et al., 2016; Sawamoto et al., 2016) . Therefore, while it is likely that reduced neurogenic capacity may indeed underlie some of the deficits seen in these animal models of depression, these discrepancies as well as the correlative nature of most studies prevent us from drawing definitive conclusions regarding the putative causal participation of newborn hippocampal neurons in the onset of depressive-like behaviors (Tanti and Belzung, 2013) .
Nevertheless, and in agreement with previous studies (Pazini et al., 2016 ) the classic antidepressant fluoxetine significantly increased neuronal commitment (i.e., the number of NeuroD-positive cells) and differentiation (i.e., the number of DCX-positive neuroblasts) both in the dorsal and ventral aspects of the hippocampal DG. In agreement, it was also demonstrated that recruitment of new hippocampal neurons by fluoxetine may contribute to the restoration of HPA axis function in models of chronic stress (Surget et al., 2011) . Furthermore, agmatine was also able to significantly enhance neuronal differentiation (i.e., the number of DCX-positive cells) along the entire hippocampal axis (i.e., the dorsal and ventral aspects of this hippocampal sub-region), further highlighting the pro-neurogenic properties of this compound.
We also evaluated the effects of corticosterone, fluoxetine, and agmatine on dendritic length and arborization, using a modified Sholl analysis (Ristanovic et al., 2006) . Interestingly, chronic treatment with either agmatine or fluoxetine, in addition to promoting an increase in the number of DCX-positive immature neurons, also increased dendritic length and arborization in these new DCX-positive neurons. These results extend those reported by Wang et al. (2008) , who found increased dendritic arborization in DCX-positive cells after chronic fluoxetine treatment (28 days), an effect that was not detected following a shorter treatment regime (5 days) . Overall, chronic fluoxetine treatment appears to affect several stages of the neurogenic process, increasing cell proliferation (Encinas et al., 2006; Malberg et al., 2000) and neuronal differentiation (Pazini et al., 2016) and present study, and stimulating dendritic branching and neuronal maturation and present study, which consequently facilitate the survival of new neurons and their integration into hippocampal networks (Santarelli et al., 2003) .
Of note, agmatine also increased dendritic complexity in immature neurons of the DG. Although the antidepressant properties of agmatine have been previously reported (Zomkowski et al., 2004; Freitas et al., 2016a; Taksande et al., 2013; Zomkowski et al., 2002) , to the best of our knowledge, this is the first study showing that chronic agmatine treatment increases both dendritic arborization and length in the hippocampal DG (particularly in the ventral aspect of this structure) in animals chronically treated with corticosterone as a model of stress. We postulate that this increase in dendritic complexity induced by agmatine may contribute for the antidepressant properties of this amine, since an increase in dendritic arborization favors connectivity of new neurons within the pre-existing hippocampal circuitry (OverstreetWadiche and Westbrook, 2006) .
The mechanisms by which agmatine increased dendritic complexity in immature neurons are still unclear. However, some of the neurochemical and molecular changes postulated to be involved in the antidepressant effect of this compound may suggest possible mechanisms. Similar to fluoxetine, agmatine is able to increase the levels of monoamines (serotonin, dopamine and noradrenaline) in the hippocampus (Freitas et al., 2015; Taksande et al., 2009 ). Furthermore, it has been demonstrated that the activation of 5-HT1A receptors is involved in the antidepressant effects of agmatine (Zomkowski et al., 2004; Jiang et al., 2008) . On the other hand, activation of this receptor subtype has been related to an increase in hippocampal neurogenesis (Santarelli et al., 2003) . Indeed, astrocytes are known to express 5-HT1A receptors, and activation of these receptors can regulate the release of neurotrophic factors that in turn will exert neurogenic effects (Azmitia et al., 1996; Manev et al., 2001 ). In line with this hypothesis, we previously showed that chronic treatment with agmatine (0.1 mg/kg, 21 days) increased BDNF expression (Freitas et al., 2014a) and BDNF signaling was also shown to mediate the antidepressant effects of acute agmatine treatment .
Overall, similarly to fluoxetine, the hippocampal neurogenic and morphological alterations promoted by agmatine may underlie, at least in part, the antidepressant (Freitas et al., 2014b; Neis et al., 2014; Zomkowski et al., 2002) and cognitive-enhancement (Arteni et al., 2002; Neis et al., 2016b; Song et al., 2014) properties of this compound.
The results showed herein, summarized in Fig. 6 , significantly extend previous data concerning the antidepressant effects of agmatine regarding its ability to cause neuroplastic changes in the hippocampus. However, further investigations of the mechanisms of action by which agmatine increases hippocampal plasticity are required. In addition, it would be of interest to measure agmatine levels in the hippocampus following corticosterone administration.
Conclusion
Several lines of evidence have proposed that an increase in hippocampal neurogenesis may mediate, at least in part, the antidepressant action of conventional antidepressants. Our results demonstrate that, similarly to fluoxetine, agmatine is able to reverse the occurrence of depressive-like behaviors induced by chronic administration of corticosterone and that this is accompanied by changes in hippocampal structural plasticity, as demonstrated by an increase in cell proliferation and dendritic complexity in the hippocampal DG. Since agmatine is an endogenous compound that presents low toxicity and has been used clinically as a nutritional supplement, the results presented here further support its use in the treatment of depression and related behaviors. Clinical trials to test its efficacy in the human population are thus warranted. Fig. 6 . Schematic representation of the main findings of the manuscript. Agmatine, similar to fluoxetine, was effective to counteract the depressive-like behavior in the TST induced by chronic corticosterone administration. Of note, these behavioral effects were accompanied by a protective effect against corticosterone-induced reduction in hippocampal cell proliferation in SGZ. Fluoxetine, but not agmatine was capable of increasing hippocampal neuronal differentiation. Notable, agmatine, similar to fluoxetine, was capable of increasing both dendritic arborization and length in the SGZ of the hippocampus. Altogether, the results suggest that the increase in hippocampal proliferation and the enhanced dendritic complexity induced by agmatine may account, at least in part, for the antidepressant-like effect of agmatine. SGZ = Subgranular Zone.
